New Haven, Connecticut 06519


This is an 8-week randomized, double-blind, placebo-controlled, parallel, fixed-dose pilot clinical trial to test the effectiveness of melatonin treatment versus placebo on symptoms of Night Eating Syndrome (NES). The investigators will also look at the effect of melatonin treatment on weight, metabolic parameters and sleep parameters in individuals with NES.

Study summary:

Night Eating Syndrome (NES) is a unique disorder characterized by a delayed pattern of food intake in which recurrent episodes of food consumption occurs after the evening meal and/or during nocturnal awakenings. Diagnostic criteria for NES include: (1) recurrent episodes of night eating, as manifested by eating after awakening from sleep or by excessive food consumption following the evening meal, (2) awareness of those eating episodes, and (3) significant distress or impairment caused by the disorder. Exclusion criteria are binge-eating disorder or another mental disorder, as well as medical disorders or medications that might better explain the disordered eating pattern. NES is also more common among patients with insomnia, eating disorders, and other psychiatric disorders. 100 participants with night eating syndrome will be recruited from the general population. They will be randomized to either a commercially available rapid-release formulation of melatonin (5 mg) or matching placebo capsules, that will be administered once a day for a total of 8 weeks. Participants will attend a screening appointment, a baseline assessment and additional research assessment visits every other week for the 8 weeks.


Inclusion Criteria: 1. 18 - 65 years of age 2. English speaking 3. Meet DSM-V (Diagnostic and Statistical Manual - version 5) criteria for Night Eating Syndrome (NES) Exclusion Criteria: 1. Unable to provide informed consent 2. Presence of alcohol/substance dependence 3. Presence of other eating disorders such as Binge Eating Disorder, Anorexia Nervosa. 4. Significant uncontrolled systemic illness (e.g. chronic renal failure, chronic liver disease, poorly controlled diabetes, poorly controlled congestive heart failure, chronic infectious disease, chronic autoimmune disease) 5. Women who are pregnant or breastfeeding 6. Allergy or hypersensitivity to melatonin



Primary Contact:

Principal Investigator
Cenk Tek, MD
Yale University

Erin Sullivan
Phone: 203-974-7317

Backup Contact:

Suat Kucukgoncu, MD
Phone: 203-974-7810

Location Contact:

New Haven, Connecticut 06519
United States

Erin Sullivan
Phone: 203-974-7317

Site Status: Recruiting

Data Source:

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.